Association of Centre of Excellence Self- Administered Questionnaire Score and Frailty Levels

February 22, 2024 updated by: Olivier Beauchet, Jewish General Hospital

Association of Centre of Excellence Self-Administered Questionnaire (CESAM) Score and Frailty Levels With Incident Health Adverse Events in Older Community Dwellers: Results of the Canadian Longitudinal Study on Aging

This study evaluates the frailty and the health adverse events in the population of the Canadian Longitudinal Study on Aging. It will be used the Centre of Excellence Self-Administered questionnaire (CESAM) which assesses frailty of older adults by providing a score and a of frailty in 4 levels.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Detailed Description

Age is broadly recognized to confer a risk for health adverse outcomes, but it is an insensitive and non-specific measure for use in individual decision-making. Frailty has been emerging to take its rightful place as a better measure for over past decades. Despite general consensus that the concept of frailty is clinically useful, the lack of agreement on its definition and the challenge of its measurement by front-line health providers mean that frailty remains only 'their apparent' to chronological age as a criterion to select older persons at risk.

Study Type

Observational

Enrollment (Estimated)

30000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Canada
    • Quebec
      • Montréal, Quebec, Canada, H3T 1E2
        • Jewish General Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

65 years and older (Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

In this research study take part people that are enrolled in the Canadian Longitudinal Study on Aging. Moreover, they are community dwellers who are frequently exposed to different health adverse events.

Description

Inclusion Criteria:

  • Being 65 years and over
  • Being enrolled in the Canadian Longitudinal Study on Aging

Exclusion Criteria:

  • Never being enrolled in the Canadian Longitudinal Study on Aging
  • Undisclosed health adverse events

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Dementia
Time Frame: around 18 months

The algorithm is a three- step process involving administration of the neuropsychological battery to develop composite score in the three domains-memory, executive function, and psychomotor speed.

The primary outcome of the study will be to determine the number of participants to whom the memory, the executive function, and the psychomotor speed are affected.
around 18 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Medication
Time Frame: around 18 months

In the maintaining contact interview, one question will be asked of all participants in relation to prescription medication use in the preceding month. A second question asks about the frequency of prescription drug use during this month.

The secondary outcome of the study will be to determine the number of the medication that the participant take during a period of time.
around 18 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Jewish General Hospital

Investigators

  • Principal Investigator: Olivier Beauchet, MD, Jewish General Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 31, 2020

Primary Completion (Estimated)

December 31, 2024

Study Completion (Estimated)

August 31, 2025

Study Registration Dates

First Submitted

June 14, 2019

First Submitted That Met QC Criteria

June 18, 2019

First Posted (Actual)

June 19, 2019

Study Record Updates

Last Update Posted (Estimated)

February 23, 2024

Last Update Submitted That Met QC Criteria

February 22, 2024

Last Verified

February 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2020-1844

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Frailty

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Albania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe